<DOC>
	<DOCNO>NCT00002021</DOCNO>
	<brief_summary>To evaluate safety efficacy intermittent intravenous ( IV ) foscarnet treatment acyclovir-resistant herpes simplex virus ( HSV ) infection AIDS patient immunocompromised patient . To evaluate necessity , efficacy , safety IV maintenance foscarnet therapy prevent recurrent disease . To confirm pharmacokinetics intermittent induction maintenance IV regimens .</brief_summary>
	<brief_title>An Open Study Foscarnet Treatment Acyclovir-Resistant Herpes Simplex Virus Patients With Acquired Immunodeficiency Syndrome Other Immunodeficiencies</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Cyclosporine . Patients must AIDS define CDC immunocompromised ( transplant patient ; hematologic malignancy recognize cellmediated immune deficiency ) . Patients must also herpes simplex virus ( HSV ) infection documented culture vitro resistance acyclovir standard laboratory susceptibility suspect resistance acyclovir acyclovir treatment failure acyclovir administer least 2 week intravenously dose 30 mg/kg/day ( comparative dose adjust renal insufficiency ) . In vitro susceptibility data must pending latter case . Patients must able give informed consent . Patients &lt; 18 year age may participate consent parent , guardian , person power attorney , provision state law regard emancipated minor . Patients must expect survival least 6 month . Prior Medication : Allowed : Cyclosporin . Ganciclovir . Exclusion Criteria Coexisting Condition : Patients follow excluded : Known allergy foscarnet . Any clinically significant pulmonary neurologic impairment ( e.g. , patient intubate comatose ) . Concurrent Medication : Excluded : Any potentially nephrotoxic agent ( except cyclosporine ) . Immunomodulators . Biologic response modifier . Investigational agent . Patients follow excluded : Known allergy foscarnet . Any clinically significant pulmonary neurologic impairment ( e.g. , patient intubate comatose ) . Prior Medication : Excluded within 7 day study entry : Any potentially nephrotoxic agent ( except cyclosporin ) . Immunomodulators . Biologic response modifier . Investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1990</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Immune Tolerance</keyword>
	<keyword>Injections , Intravenous</keyword>
	<keyword>Herpes Simplex</keyword>
	<keyword>Immunity , Cellular</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>